The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Expect to see the pace accelerate at the Eli Lilly ... with the Indiana Economic Development Corp. to buy 1,400 acres on the southern side of LEAP on the northside of Ind. 32 on Lebanon’s ...

Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon’s north side as weather warms. The $9 million pharmaceutical complex is about 7% complete, Jeff Wagner, community ...

Expect to see the pace accelerate at the Eli ... Lilly is the flagship, and sole, tenant. But Meta is reportedly in negotiations with the Indiana Economic Development Corp. to buy 1,400 acres on the ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly pre-announced a sizable Q4 2024 revenue miss headed into the big J.P. Morgan healthcare investor conference, but the biopharma reported massive growth. A lot of the quarterly ...